INTRODUCTION
The differentiation of liver dysfunction after orthotopic liver transplantation can be difficult. Possibilities include rejection. ischemic harvest injury. vascular thrombosis. bile duct complications. hemolysis. and hepatitis IStarz] et al. 1982; Esquivel et al. 1985] . The treatment is different for each possibility. and therefore there is a critical need to establish the correct diagnosis. One entity that has not received enough attention as both the cause of graft dysfunction. and significant morbidity and mortality is CMV hepatitis. To our knowledge. this is the first report to characterize and describe a series of patients with pathologically proven CMV hepatitis following orthotopic liver transplantation. On the basis of this review. recommendations for the diagnosis and management of CMV hepatitis during liver transplantation are presented.
MATERIALS AND METHODS
Between March. 1980 and September. 1985 . after the advent of combined immunosuppression with cyclosporine and prednisone, 553 orthotopic liver transplants in 429 patients were performed at the University of Pittsburgh. with the complete approval of the University's Institutional Review Board.
More specific and aggressive management of rejection has resulted in improved patient and graft survival in an ever increasing patient population. One of the most useful adjuncts contributing to this improvement has been the evolution of a liberal policy of percutaneous liver biopsies. Biopsies are now routinely performed whenever there is clinical suspicion of acute rejection. and to help evaluate fever and biochemical abnormalities when a diagnosis is not clear.
The pathologic specimens from all patients undergoing orthotopic liver transplantation since 1980 were reviewed. Only those patients with pathologically proven CMV hepatitis were included in this analysis.
Patients
Seventeen patients. 13 males and 4 females, ranging in age from 2 years to 53 years. were identified. There were seven pediatric patients and ten adult patients. Eight of the patients had more than one transplant. Table I lists chronologically all of the patients diagnosed as having CMV hepatitis. A wide spectrum of pretransplant pathologic diagnoses existed in this group of patients, but the preoperative diagnosis was not prognostically significant (biliary atresia-four; primaf) biliary cirrhosis-two; alpha-J -antitf)-psin deficiency-two; sclerosing cholangitis-two; idiopathic cirrhosis-two: 
Died
ReT. IDummer et al. 1983] . These specimens are routinely cultured for CMV in all patients every 2 weeks during hospitaliza t ion. (Table II) CMV infection is diagnosed by serologic changes and/or isolation of the virus. Primary CMV infections are diagnosed by seroconversion. Eight of the patients in this series had primary CMV infection. Three patients (Ol Tx #310. 472. 480) were seronegative prior to transplant and seroconverted after transplantation: pretransplant serology was not available on one patient (OL Tx 1481). but he was seronegative posttransplant and later seroconverted. Of the remaining four patients. all were seronegative either pre-or posttransplants: later serum samples were not available to confirm seroconversion.
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RESULTS
Evaluation of Serology and Culture of CMV Infections
Reactivation infection is diagnosed by a four-fold or greater rise in antibody titer. One patient had reactivation infection confirmed by a diagnostic rise. Five patients had "probable" reactivation infection. as indicated by seropositivity prior to and/or posttransplant. although a diagnostic rise could not be demonstrated because samples were not available. In three patients, the presence of primaT) or reactivated CMV infection could not be determined due to a lack of appropriate serum samples.
CMV was isolated from one or more specimens (i.e .
• blood, urine. throat) in 15 of the 17 patients. The associated bacterial and fungal infections found in these patients are also listed in Table II . Table III summarizc:s the fever and hepatic function profiles for these patients. Fifteen of 17 patients had fever for more than 5 days. with a range of 5-68 days and a mean of 22 !: 5.5 days. One patient was afebrile throughout the course of the disease. and one patient had fever for a single day. The highesr temperatures ranged from 38.5OC to 4O.5°C. and in some patients. fever persisted after the resolution of biochemical abnormalities.
Evaluation of Clinical Signs and Symptoms
Bilirubin was elevated in 14 of the 17 patients. When the diagnosis was established at retransplantation, bilirubin was substantially higher than when the diagnosis was established by biopsy. The highest values of 44 mgjdl and 20.4 mg/dl occurred in patients undergoing retransplantation with simultaneous CMV hepatitis and ischemic injury.
SGOT was elevated in 16 of J7 patients at diagnosis and continued to rise after diagnosis in 8 patients. Most elevations were in the 100-300 It.: range. but in three patients. values were greater than 700 IU. SGPT was elevated in 16 of 17 patients and continued to rise in 6 patients after the diagnosis "'as established. Most values were in the 50-200 IU range. and five values were greater than 400 IU. It is of that note only three patients developed leukopenia (",hite blood cell count of less than 3.000). and only five patients developed thrombocY1openia (platelet count less than 100,000).
Evaluation of Management
The management of CM\' hepatitis has been altered by our increasing use of percutaneous liver biopsies. In our series of 17 patients. 5 of the first 8 patients having CMY hepatitis were only diagnosed at the time of retransplantation; therefore only 3 of these first 8 patients were diagnosed by biopsy. However. all of the last nine patients to be diagnosed as having CMY hepatitis were diagnosed by percutaneous biopsy. The use of percutaneous biops~ significantly facilitates the establishment of the diagnosis of CMY hepatitis and fa"'orably influenced patient survival in this series. Only 4 of the 12 patients diagnosed by biopsy have died, whereas 4 of 5 patients who were unexpectedly diagnosed at retransplantation have died.
When the diagnosis of CMV hepatitis was established by biopsy and no rejection was present. the management was the reduction of cyclosporine and/or prednisone (eight patients). In one other such patient. there was no reduction in maintenance immunosu~ pression. In most patients. cyclosp:)rine was lowered in order to achieve R I A levels of 300-400 ng/per dL Maintenance prednisone doses were reduced to 5. 10, or 15 mgjday. Difficulty in patient management arose when a biopsy revealed concurrent CMY hepatitis and rejection. This occurred in four patients (OLTx 291. 394. 481,and 514). and it required careful individualization of management. It was always necessary to treat the rejection comp:)nent. and it was not uncommon to find worsening of the CMV hepatitis after therapy for rejection. Following resolution of rejection. immunosuppression had to be closely monitored and conceivably lowered to allo" resolution of the CMV hepatitis.
The "orst outcome was evident in a group of patients who underv.ent retransplantation with the diagnosis of endstage rejection but who in fact had CMV hepatitis with no rejection at the time of retransplantation. All three of these patients (OL Tx 203,257,348) ultimately expired. Three patients (OL Tx 480, 514, and 556) were recognized as having CMV hepatitis prior to receiving therapy for acute rejection. Therefore. 3 of 17 patients developed CMY hepatitis with no treatment for rejection, and 14 of 17 patients had from one to four courses of treatment for acute rejection prior to developing CMY hepatitis. These are summarized in Table I .
, Fi, I. AI ViTally transrormed ~JIs are \ar~. with nuclear inclusions noted in some sections. but cytoplasmic chang~ are visible (arro.,.) even ""here nuclear inclusions arc not e--ident (HIE ) ( 198) . B'lmmunopcroxidasc staining usin& anti-CMV antibod) reveals the presenc:c or cytoplasmic antigen. the nuclear inclUSIOn being unstained (DAB)( 257). 0 CMV antigen can be detected in degenerating ~II rragmcnu engulred by neutrophils. 5«n here I.S dark precipitate (aITO\\s) (DAB )( 265).
Evaluation of Biopsies and Differentiation from Rejection (Table I) Clusters of neutrophils. often forming a microabscess within the lobule. were a clue to the presence of eMV. and their presence sparked a search for the virus. Virus was found almost entirely within hepatocytes. more rarely in Kupfer cells. endothelial cells. or biliary epithelium. In adults. where concomiLant ischemic changes were more common. virus was noted to be in periportal hepatoc),les and Kupfer cells as well as in biliaT) epithelial cells. Rapidly dividing cells in granulation tissue around abscesses or at anastomotic lines appeared to be particularly vulnerable. These cells were often heavily involved. while surrounding tissues were devoid of CMV. Neutrophil aggregates were less prominent in adults. in whom mononuclear cells were more conspicuous.
Infestation varied markedly. from 0.2 to 23 infected cells per mm 2 of tissue. Hematoxylin·eosin proved as sensitive for the diagnosis as anti·CMV antibody Staining of viral antigen using the anti·CMV antibody demonstrated cytoplasmic virus only in those cells displaying CYlopathic effect. In no instance was unsuspected infection demonstrated by use of the antibody alone. However. the neutrophil clusters often surrounded cell debris in which CMV antigen was detectable. even through no inclusions were noted (Fig. I) .
The presence and severity of other concomitant processes could be assessed independently of the eMV hepatitis. Inflammation in the hepatitis was limited to neutrophils and mononuclear cells in close contact with virally infected cells. Rejection could be independently e\'a)uated and was absent in five patients and present . . .
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degr~ of ~verity in 12. There wa~ no rdationship between the extent of the: CMY infestation and the severity of the rejection changc-5- (Fig 2) .
DISCUSSION
Although CMY hepatitis has been well rerognized in both the normal and the immunocompromised host. this is the first report to describe this entity as a recurrent problem in orthotopic liver transplantation. While hepatitis is oommon in CMY infections. it is usually not severe. even in other types of transplant patients (Ten Napel et al. 1984) . Unique concerns arise when CMY infection associated with abnormalities in bilirubin and liver enzymes occur following liver transplantation The differential of liver dysfunction after orthotopic liver transplantation includes rejection. ischemic injury. vascular thrombosis. bile duct complications. hemolysis. and hepatitis.
CMV hepatitis arises relatively late after liver transplantation (15-132 days. with a mean of 44 ~ 6 days) and virtually always is accompanied by prolonged fever (15 of 17 patients. with a mean duration of fever of 22 :! 5.5 days). Practically. this means that. the critical differentiation is between hepatitis and rejection. The quickest and most definitive means of discriminating between these two entities is a percutaneous liver biopsy. We established the diagnosis of CMV hepatitis in the last nine patients by percutaneous biopsy. while we established the diagnosis at retransplantation in five of the first eight patients. This difference arose in our series becluse we have liberalized our policy concerning percutaneous biopsies in the last I to :! years. When the diagnosis was first established al retransplantation. four of the five patients diagnosed in this manner died. while only 4 of 12 patients diagnosed on percutaneous biopsy have died. Other reports have attempted to document CMV hepatitis in immunocompromised patients. such as kidney. heart. heart·lung. and bone marrow transplant recipients [Dummer et al. 1983; . But few of these reports have histopathologic confirmation of the diagnosis of CMV hepatitis. whereas the histologic confirmation of this diagnosis was obtained in all of the patients in this series. In addition to histologic confirmation. the CMV virus was cultured in five pediatric and one adult liver specimens. CMY was isolated on culture of other sites in 15 of the 17 patients. The timing of these isolations. however. was not alway~ clinically useful. as viral cultures can take 2 to 3 weeks. and frequently the cultures 'Were not positive until after we had established the diagnosis on biopsy or retransplant. Infection is froquently asymptomatic . Hence these cultures are insufficient evidence for the diagnosis of CMV hepatitis.
Interestingly. patients with both primary and reactivation infections developed CMY hepatitis. and the patients' pretransplant serologic status was not prognostically significant. Eight patients with CMV hepatitis had primary CMV infection. and in six patients. the hepatitis followed eMV reactivation. We were unable to interpret the serologic data in three patients. The rate of primary CMV infections among liver transplant recipients is reported to be 289C IHo et al. 1983] . As 579C of our patients de\'eloped hepatitis following a primary CMV infection. this suggests that patients with a primaf) infection are at greater risk for developing hepatitis. In eight patients with primary CMV infection. there were three deaths. and five patients survived. In the six patients wilh reacti\·ated disease. there were three deaths and three survivors. Also. the site of CMV isolation. namely in the blood. has been reported to be an indicator of more severe or Iife·threatening infection [Armstrong et al. 1971; Pass el al. 1980 ]. This did not prove to be the case in the analysis of the present patient group. The diagnosis of CMV hepatiti!o was made .... hen a single v'iral inclusion was identified. Infestalion v. as seen to increase markedl) in some instances when concomitant rejection was aggressivel) treated. Because the inflammatory response provoked by the CMY was localized to the infected cells. there was very little overlap with other simultaneous processes. In particular. the portal inflammatory profile characteristic or rejection was not provoked by the CMV hepatitis alone. Severe hepatitis .... ith hea\') infestation was nOled without portal infiltrate of any degree. even though it must be recognized that antirejection therapy can alter the cellular profile of the rejection response.
Starr et a111984] have shown that the natural killing against CMV-infected target cells was depressed in kidney recipients for 2 years after transplantation but that a reduction in immunosuppression in these patients resulted in temporal association with resolution of CMY disea~. In addition. CMV is felt to be an immunosuppressive agent on its own. and therefore. if full-maintenance immunosuppression is maintained during the course of the disea~. the patient may in fact be over-immunosuppressed and susceptible to additional bacterial or opportunistic infections.
At present. when a diagnosis of CMY hepatitis is established in a liver transplant recipient in whom there is no evidence of rejection. our management is to lower the d~ of cyclosporine and/or prednisone. With the confirmation ofCMV hepatitis. the therapeutic levels of cyclosporine of 700-1.000 ns/dl are usually lowered 10 300-400 ng/d!. When there is clinical resolution of the hepatitis. cyclosporine is then returned to therapeutic levels. Prednisone is usually lowered from maintenance at 20 mg/day to 5. 10. or 15 ms/day depending on the clinical ~verity of the di5ea~ (in children. the dose is frequently lowered even rurther). A problem arises in the management of patients who have concomitant CMV infection and rejection. as occurred in four patients. In this group of patients. our initial concern is directed toward the treatment of rejection. Ho .... ever. as we treal rejection. it is not uncommon that the eMV hepatitis worsens. and after resolution of rejection. we frequentl) have to deal ..... ith the CMV hepatitis. This may require the reduction in the maintenance levels of immunosuppression until the CMV disea~ has resolved: full-maintenance immunosuppression is then resumed .
CM V hepatitis afler orthotopic liver transplantation is a definite clinical entity with specific signs and symptoms. ~rologic and culture findings. and pathologic features; it is being recognized with increased frequency in both adult and pediatric patients. The differentiation ofCM\' hepatitis from other causes of liver dysfunclion is essential in order to institute appropriate management. Currentl) it is best achieved b) a high index of suspicion and the Judicious u~ of liver biopsies.
We ha\·e. for the past tv.o years used a monoclonal antibody to earl) intermediate CMY antigen (Chemican. EI Segundo. CA) ..... hich can. after trypsin digestion. demonstrate nuclear antigen before infected cells are morphologically transferred. It is thus possible to make the diagnosis of CMY on biops) of an apparently uninvolved specimen. This ha~ not changed an) of the conclusions presented in this paper.
